Skip to main content
SpringerLink
Log in

Radium-223 and Other Radiopharmaceuticals in Prostate Cancer

  • Chapter
  • First Online:
Book cover Management of Castration Resistant Prostate Cancer

Part of the book series: Current Clinical Urology ((CCU))

  • 880 Accesses

Abstract

Prostate cancer is a bone-metastatic disease but until recently bone-targeted therapies had never demonstrated improvements in survival. Prior radiopharmaceuticals have demonstrated palliative responses in bone-metastatic castrate-resistant prostate cancer (CRPC) but no survival benefit. Radium-223 is a novel bone-seeking radionuclide that is predominately an alpha-emitter. It releases a total of four alpha particles with a half-life of approximately 11 days. Radium targets to bone as a calcium-mimetic and binds to the inorganic matrix of newly formed bone, which is typically found in osteoblastic metastases. A phase 3 trial demonstrated an improvement in overall survival in bone metastatic CRPC in patients without visceral disease. Radium-223 was given for six doses using monthly intravenous injections. The drug was well tolerated with minimal myelosuppression. Radium-223 has now been approved for use by multiple regulatory authorities around the globe.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. http://www.nobelprize.org/nobel_prizes/physics/laureates/1901/rontgen-facts.html.

  2. http://www.nobelprize.org/nobel_prizes/physics/laureates/1903/becquerel-bio.html.

  3. Curie MS. Radium and radioactivity. Century Mag. 1904;461–466.

    Google Scholar 

  4. Mould RF. The discovery of radium in 1898 by Maria Sklodowska-Curie (1867–1934) and Pierre Curie (1859–1906) with commentary on their life and times. Br J Radiol. 1998;71:1229–54.

    Article  CAS  PubMed  Google Scholar 

  5. http://www.nobelprize.org/nobel_prizes/themes/physics/curie/.

  6. Macintyre J. Radium and its therapeutic effects. Br Med J. 1903;2:1524–6.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  7. http://www.americanbrachytherapy.org/aboutbrachytherapy/history.cfm.

  8. Sartor O, Hoskin P, Bruland OS. Targeted radio-nuclide therapy of skeletal metastases. Cancer Treat Rev. 2013;39:18–26.

    Article  CAS  PubMed  Google Scholar 

  9. Friedell HL, Storaasli JP. The use of radioactive phosphorus in the treatment of carcinoma of the breast with widespread metastases to bone. Am J Roentgenol Radium Ther. 1950;64:559–75.

    CAS  PubMed  Google Scholar 

  10. Maxfield JR, Maxfield JGS, Maxfield WS. The use of radioactive phosphorus and testosterone in metastatic bone lesions from breast and prostate. South Med J. 1958;51:320–8.

    Article  PubMed  Google Scholar 

  11. Tomblyn M. The role of bone-seeking radionuclides in the palliative treatment of patients with painful osteoblastic skeletal metastases. Cancer Control. 2012;19:137–44.

    CAS  PubMed  Google Scholar 

  12. Porter AT, McEwan AJ, Powe JE, et al. Results of a randomized phase-III trial to evaluate the efficacy of Sr-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Radiat Oncol Biol Phys. 1993;25:805–13.

    Article  CAS  PubMed  Google Scholar 

  13. Serafini AN, Houston SJ, Resche I, et al. Palliation of pain associated with metastatic bone cancer using samarium-153 EDTMP: a double-blind placebo-controlled clinical trial. J Clin Oncol. 1998;16:1574–81.

    CAS  PubMed  Google Scholar 

  14. Sartor O, Reid RH, Hoskin PJ, et al. Samarium-153-EDTMP complex for treatment of painful bone metastases in hormone-refractory prostate cancer. Urology. 2004;63:940–5.

    Article  PubMed  Google Scholar 

  15. http://www.epa.gov/rpdweb00/understand/beta.html.

  16. http://www.epa.gov/rpdweb00/understand/alpha.html.

  17. Ritter MA, Cleaver JE, Tobias CA. High-LET radiations induce a large proportion of non-rejoining DNA breaks. Nature. 1977;14(266):653–5.

    Article  Google Scholar 

  18. Bruland ØS, Jonasdottir TJ, Fisher DR, Larsen RH. Radium-223: from radiochemical development to clinical applications in targeted cancer therapy. Curr Radiopharm. 2008;1:203–8.

    Article  CAS  Google Scholar 

  19. Nilsson S, Balteskard L, Fosså SD, et al. First clinical experiences with alpha emitter radium-223 in the treatment of skeletal metastases from breast and prostate cancer. Clin Cancer Res. 2005;11: 4451–9.

    Article  CAS  PubMed  Google Scholar 

  20. Nilsson S, Franzén L, Parker C, et al. Bone-targeted radium-223 in symptomatic, hormone refractory prostate cancer: a randomized, placebo-controlled, phase 2 study. Lancet Oncol. 2007;8:587–94.

    Article  CAS  PubMed  Google Scholar 

  21. Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369:213–23.

    Article  CAS  PubMed  Google Scholar 

  22. Sartor AO, Amariglio R, Wilhelm S, et al. Correlation between baseline variables and survival in the radium-223 dichloride (Ra-223) phase III ALSYMPCA trial with attention to total ALP changes. J Clin Oncol. 2013;31:(suppl; abstr 5080).

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Tulane Cancer Center, Tulane Hospital, Hem/Onc, 1430 Tulane Avenue, SL-78, New Orleans, LA, 70112, USA

    Oliver Sartor MD & Brian Lewis MD

Authors
  1. Oliver Sartor MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Brian Lewis MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Oliver Sartor MD .

Editor information

Editors and Affiliations

  1. Department of Surgery, University of Montreal Hospital Center, Montreal, Québec, Canada

    Fred Saad

  2. Department of Oncology, The Johns Hopkins University, Baltimore, Maryland, USA

    Mario A. Eisenberger

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer Science+Business Media New York

About this chapter

Cite this chapter

Sartor, O., Lewis, B. (2014). Radium-223 and Other Radiopharmaceuticals in Prostate Cancer. In: Saad, F., Eisenberger, M. (eds) Management of Castration Resistant Prostate Cancer. Current Clinical Urology. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-1176-9_11

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-1176-9_11

  • Published:

  • Publisher Name: Humana Press, New York, NY

  • Print ISBN: 978-1-4939-1175-2

  • Online ISBN: 978-1-4939-1176-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation